BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18455284)

  • 1. Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach.
    Lodewyck T; Cornelissen JJ
    Blood Rev; 2008 Nov; 22(6):293-302. PubMed ID: 18455284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality.
    Meijer E; Cornelissen JJ
    Semin Oncol; 2008 Aug; 35(4):449-57. PubMed ID: 18692695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.
    Juliusson G; Karlsson K; Lazarevic VLj; Wahlin A; Brune M; Antunovic P; Derolf A; Hägglund H; Karbach H; Lehmann S; Möllgård L; Stockelberg D; Hallböök H; Höglund M;
    Cancer; 2011 Sep; 117(18):4238-46. PubMed ID: 21387283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?
    Song KW; Lipton J
    Bone Marrow Transplant; 2005 Aug; 36(3):183-91. PubMed ID: 15937497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
    Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
    Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
    Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic stem cell transplantation in the management of acute myeloid leukemia].
    Schmid C; Kolb HJ
    Med Klin (Munich); 2007 Apr; 102(4):317-23. PubMed ID: 17426935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation.
    Parkman R; Cohen G; Carter SL; Weinberg KI; Masinsin B; Guinan E; Kurtzberg J; Wagner JE; Kernan NA
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):919-27. PubMed ID: 16920557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
    Yang DH; Lee JJ; Mun YC; Shin HJ; Kim YK; Cho SH; Chung IJ; Seong CM; Kim HJ
    Am J Hematol; 2007 Jan; 82(1):1-5. PubMed ID: 16986129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years.
    Giebel S; Labopin M; Holowiecki J; Labar B; Komarnicki M; Koza V; Masszi T; Mistrik M; Lange A; Hellmann A; Vitek A; Pretnar J; Mayer J; Rzepecki P; Indrak K; Wiktor-Jedrzejczak W; Wojnar J; Krawczyk-Kulis M; Kyrcz-Krzemien S; Rocha V
    Ann Hematol; 2009 Oct; 88(10):1005-13. PubMed ID: 19301005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants.
    Hemmati PG; Terwey TH; le Coutre P; Vuong LG; Massenkeil G; Dörken B; Arnold R
    Eur J Haematol; 2011 Apr; 86(4):305-16. PubMed ID: 21265883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
    Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
    Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide vaccines for patients with acute myeloid leukemia.
    Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
    Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
    Loren AW; Porter DL
    Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia.
    Cornelissen JJ; Löwenberg B
    Hematology Am Soc Hematol Educ Program; 2005; ():151-5. PubMed ID: 16304373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximum supportive care, standard conditioning and allogeneic stem cell transplantation for elderly patients with acute myelogenous leukemia.
    Petersen FB; Ford CD
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S7-9. PubMed ID: 19561415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease.
    Valcárcel D; Martino R; Piñana JL; Sierra J
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S35-7. PubMed ID: 19561412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.
    Hemmati PG; Terwey TH; Na IK; le Coutre P; Jehn CF; Vuong LG; Dörken B; Arnold R
    Eur J Haematol; 2015 May; 94(5):431-8. PubMed ID: 25220715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.